The DOI matches its Crossref record; 231 of the 232 references it cites were found in a registry or an index.
MYC on the Path to Cancer
Open accessAbstract
The MYC oncogene contributes to the genesis of many human cancers. Recent insights into its expression and function have led to therapeutic opportunities. MYC's activation by bromodomain proteins could be inhibited by drug-like molecules, resulting in tumor inhibition in vivo. Tumor growth can also be curbed by pharmacologically uncoupling bioenergetic pathways involving glucose or glutamine metabolism from Myc-induced cellular biomass accumulation. Other approaches to halt Myc on the path to cancer involve targeting Myc-Max dimerization or Myc-induced microRNA expression. Here the richness of our understanding of MYC is reviewed, highlighting new biological insights and opportunities for cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Myc oncogene, including its three subtypes C-Myc, N-Myc, and L-Myc, is believed to act as a transcriptional “amplifier” that can trigger a variety of oncogenic transcriptional programs in different types of cancer.410,411”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [410]
In the citing paper
“Overexpression or hyperactivation of Myc is one of the most common occurrences in cancer, making it a key factor in oncogenesis.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [410]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Identification of c- MYC as a Target of the APC Pathway
He, T.-C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · Science · doi:10.1126/science.281.5382.1509 · Cited by 4,566
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,888
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
c-Myc-regulated microRNAs modulate E2F1 expression
O'Donnell, K. A., Wentzel, E. A., Zeller, K. I., Dang, C. V., & Mendell, J. T. (2005) · Nature · doi:10.1038/nature03677 · Cited by 2,347
Self-citationAmplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., VARMUS, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,261
Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor
Kelly, K., Cochran, B., Stiles, C. D., & Leder, P. (1983) · Cell · doi:10.1016/0092-8674(83)90092-2 · Cited by 2,227
The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation
Wang, R., Dillon, C. P., Shi, L. Z., Milasta, S., Carter, R., Finkelstein, D., McCormick, L. L., Fitzgerald, P., Chi, H., Munger, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.021 · Cited by 2,140 · cited 2×
“Loss of Myc was associated with profoundly diminished expression of genes involved in metabolism and the inability for normal primary T cells to grow and proliferate (Wang et al., 2011a).”
BackgroundGao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124
Self-citation
Flagged first, then by citations
1 of the 232 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–400 of 1,008
Immunogenic cell death in colon cancer prevention and therapy
Ruan, H., Leibowitz, B. J., Zhang, L., & Yu, J. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23183 · Cited by 125
AKIRIN2 controls the nuclear import of proteasomes in vertebrates
de Almeida, M., Hinterndorfer, M., Brunner, H. L., Grishkovskaya, I., Singh, K., Schleiffer, A., Jude, J., Deswal, S., Kalis, R., Vunjak, M., et al. (2021) · Nature · doi:10.1038/s41586-021-04035-8 · Cited by 123
Mutual regulation of lactate dehydrogenase and redox robustness
Lin, Y., Wang, Y., & Li, P. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.1038421 · Cited by 122
Mechanisms and functions of Nrf2 signaling in Drosophila
Pitoniak, A., & Bohmann, D. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.020 · Cited by 129
Iron Deprivation in Cancer––Potential Therapeutic Implications
Heath, J. L., Weiss, J. M., Lavau, C., & Wechsler, D. S. (2013) · Nutrients · doi:10.3390/nu5082836 · Cited by 125
Du, Y., Wei, N., Ma, R., Jiang, S., & Song, D. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02952-6 · Cited by 124
MYC-dependent oxidative metabolism regulates osteoclastogenesis via nuclear receptor ERRα
Bae, S., Lee, M. J., Mun, S. H., Γιαννοπούλου, Ε., Yong‐Gonzalez, V., Cross, J. R., Murata, K., Giguère, V., van der Meulen, M. C. H., & Park‐Min, K. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89935 · Cited by 123
MYC-Regulated Mevalonate Metabolism Maintains Brain Tumor–Initiating Cells
Wang, X., Huang, Z., Wu, Q., Prager, B. C., Mack, S. C., Yang, K., Kim, L. J. Y., Gimple, R. C., Shi, Y., Lai, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0114 · Cited by 125
Ning, J.-F., Stanciu, M., Humphrey, M. R., Gorham, J., Wakimoto, H., Nishihara, R., Lees, J. A., Zou, L., Martuza, R. L., Wakimoto, H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10993-5 · Cited by 120
Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and TherapiesPreprint
Puca, L., Vlachostergios, P. J., & Beltran, H. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030593 · Cited by 120
Andrews, F. H., Singh, A. R., Joshi, S., Smith, C. A., Morales, G. A., Garlich, J. R., Durden, D. L., & Kutateladze, T. G. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613091114 · Cited by 119
Mottini, C., Napolitano, F., Li, Z., Gao, X., & Cardone, L. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.023 · Cited by 125
c-Myc inactivation of p53 through the pan-cancer lncRNA MILIP drives cancer pathogenesis
Feng, Y., Liu, X., Liu, T., Ji, Q., Wu, Y., Li, J., Gao, W., Zhang, Y. Y., La, T., Tabatabaee, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18735-8 · Cited by 119
Modulation of endothelium function by fatty acids
Mallick, R., & Duttaroy, A. K. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04260-9 · Cited by 129
Shostak, A., Ruppert, B., Ha, N., Bruns, P., Toprak, U. H., ICGC MMML-Seq Project, Lawerenz, C., Lichter, P., Radlwimmer, B., Eils, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11807 · Cited by 120
Zhao, X. L., Lwin, T., Zhang, X., Huang, A., Wang, J., Márquez, V. E., Chen‐Kiang, S., Dalton, W. S., Sotomayor, E., & Tao, J. (2013) · Leukemia · doi:10.1038/leu.2013.94 · Cited by 119
Ran GTPase: A Key Player in Tumor Progression and Metastasis
Boudhraa, Z., Carmona, E., Provencher, D. M., & Mes‐Masson, A. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00345 · Cited by 117
Regulation of CD47 expression in cancer cells
Huang, C.-Y., Ye, Z.-H., Huang, M., & Lu, J. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100862 · Cited by 128
Signaling, metabolism, and cancer: An important relationship for therapeutic intervention
Vaghari‐Tabari, M., Ferns, G. A., Qujeq, D., Andevari, A. N., Sabahi, Z., & Moein, S. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30276 · Cited by 126
Cooperation between bHLH transcription factors and histones for DNA access
Michael, A. K., Stoos, L., Crosby, P., Eggers, N., Nie, X. Y., Makasheva, K. A., Minnich, M., Healy, K. L., Weiss, J., Kempf, G., et al. (2023) · Nature · doi:10.1038/s41586-023-06282-3 · Cited by 116
Huang, R., & Zong, X. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.04.005 · Cited by 117
Neuroblastoma pathogenesis: deregulation of embryonic neural crest development
Tomolonis, J., Agarwal, S., & Shohet, J. M. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2747-0 · Cited by 122
Organ-Specific Cancer Metabolism and Its Potential for Therapy
Elia, I., Schmieder, R., Christen, S., & Fendt, S. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_10 · Cited by 112
Lei, T., Hu, Q., Lei, P., & Hu, Y. (2021) · Cancer Science · doi:10.1111/cas.15131 · Cited by 114
MicroRNAs as regulators and mediators of c-MYC function
Jackstadt, R., & Hermeking, H. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.04.003 · Cited by 117
Liao, P., Zeng, S. X., Zhou, X. Y., Chen, T., Zhou, F., Cao, B., Jung, J. H., Sal, G. D., Luo, S., & Lu, H. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.11.006 · Cited by 115
Seliger, B. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122168 · Cited by 111
Wiegering, A., Uthe, F. W., Jamieson, T. J., Ruoss, Y., Hüttenrauch, M., Küspert, M., Pfann, C., Nixon, C., Herold, S., Walz, S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1040 · Cited by 119
Kawasaki, Y., Komiya, M., Matsumura, K., Negishi, L., Suda, S., Okuno, M., Yokota, N., Osada, T., Nagashima, T., Hiyoshi, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.015 · Cited by 114
Pashaei, E., Pashaei, E., Ahmady, M., Özen, M., & Aydın, N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179543 · Cited by 113
Hallal, S. M., Mallawaaratchy, D. M., Wei, H., Ebrahimkhani, S., Stringer, B. W., Day, B. W., Boyd, A., Guillemin, G. J., Buckland, M. E., & Alexander, K. L. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1385-1 · Cited by 119
Beaulieu, M.-È., Castillo, F., & Soucek, L. (2020) · Cells · doi:10.3390/cells9041038 · Cited by 110
MYC assembles and stimulates topoisomerases 1 and 2 in a “topoisome”
Das, S., Kuzin, V., Cameron, D. P., Sanford, S., Jha, R. K., Nie, Z., Rosello, M. T., Holewinski, R. J., Andrésson, Þ., Wiśniewski, J., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.11.016 · Cited by 112
Immunoediting instructs tumor metabolic reprogramming to support immune evasion
Tsai, C., Chuang, Y., Li, X., Yu, Y.-R., Tzeng, S., Teoh, S. T., Lindblad, K. E., Matteo, M. D., Cheng, W.-C., Hsueh, P., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.12.003 · Cited by 116
Yu, K., Shin, J., Kim, J.-J., Koog, M. G., Lee, J. Y., Choi, S. W., Kim, H.-S., Seo, Y., Lee, S., Shin, T., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2014.12.038 · Cited by 112
The Role of Pontin and Reptin in Cellular Physiology and Cancer Etiology
Mao, Y.-Q., & Houry, W. A. (2017) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2017.00058 · Cited by 113
MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels
Lu, Y., Hu, Z., Mangala, L. S., Stine, Z. E., Hu, Z., Jiang, D., Xiang, Y., Zhang, Y., Pradeep, S., Rodriguez‐Aguayo, C., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0815 · Cited by 111
Self-citationRibosomal proteins L5 and L11 co-operatively inactivate c-Myc via RNA-induced silencing complex
Liao, J.-M., Zhou, X. Y., Gatignol, A., & Lu, H. (2013) · Oncogene · doi:10.1038/onc.2013.430 · Cited by 111
Alonso‐Curbelo, D., Riveiro‐Falkenbach, E., Pérez‐Guijarro, E., Cifdaloz, M., Karras, P., Osterloh, L., Megı́as, D., Cañón, E., Calvo, T. G., Olmeda, D., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.030 · Cited by 114
Enhancer RNAs in cancer: regulation, mechanisms and therapeutic potential
Lee, J., Xiong, F., & Li, W. (2020) · RNA Biology · doi:10.1080/15476286.2020.1712895 · Cited by 108
Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy.
Ju, X., Zhang, H., Zhou, Z., & Wang, Q. (2020) · PubMed Central · Cited by 108
mTORC1 promotes cell growth via m6A-dependent mRNA degradation
Cho, S., Lee, G., Pickering, B. F., Jang, C., Park, J. H., He, L., Mathur, L., Kim, S.-S., Jung, S., Tang, H.-W., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.03.010 · Cited by 113
Pandkar, M. R., Sinha, S., Samaiya, A., & Shukla, S. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101758 · Cited by 126
Synergistic effect of JQ 1 and rapamycin for treatment of human osteosarcoma
Lee, D. H., Qi, J., Bradner, J. E., SAID, J. W., Doan, N., Forscher, C. A., Yang, H. H., & Koeffler, H. P. (2014) · International Journal of Cancer · doi:10.1002/ijc.29269 · Cited by 110
Strategically targeting MYC in cancer
Posternak, V., & Cole, M. D. (2016) · F1000Research · doi:10.12688/f1000research.7879.1 · Cited by 108
Metabox: A Toolbox for Metabolomic Data Analysis, Interpretation and Integrative Exploration
Wanichthanarak, K., Fan, S., Grapov, D., Barupal, D. K., & Fiehn, O. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171046 · Cited by 111
Kumar, S., & Agnihotri, N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.182 · Cited by 109
Wu, H.-L., Yang, T.-Y., Li, Y., Ye, W.-L., Liu, F., He, X.-S., Wang, J.-R., Gan, W.-J., Li, X.-M., Zhang, S., et al. (2020) · Hepatology · doi:10.1002/hep.30801 · Cited by 82
Zhang, H., Xu, A.-D., Sun, X., Yang, Y., Zhang, L., Bai, H., Ben, J., Zhu, X., Li, X., Yang, Q., et al. (2020) · Circulation Research · doi:10.1161/circresaha.119.316428 · Cited by 109
Targeting nucleotide metabolism as the nexus of viral infections, cancer, and the immune response
Ariav, Y., Ch’ng, J., Christofk, H. R., Ron‐Harel, N., & Erez, A. (2021) · Science Advances · doi:10.1126/sciadv.abg6165 · Cited by 109
Cellular Pliancy and the Multistep Process of Tumorigenesis
Puisieux, A., Pommier, R. M., Morel, A., & Lavial, F. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.007 · Cited by 114
Xia, Y., Ye, B., Ding, J., Yu, Y., Alptekin, A., Thangaraju, M., Prasad, P. D., Ding, Z., Park, E. J., Choi, J.-H., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3541 · Cited by 108
PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression
Liu, M., Yao, B., Gui, T., Guo, C., Wu, X., Li, J., Ma, L., Deng, Y., Xu, P., Wang, Y., et al. (2020) · Theranostics · doi:10.7150/thno.42047 · Cited by 108
MYC in Regulating Immunity: Metabolism and Beyond
Gnanaprakasam, J. R., & Wang, R. (2017) · Genes · doi:10.3390/genes8030088 · Cited by 111
Chen, J., Ding, C., Chen, Y., Hu, W., Lu, Y., Wu, W., Zhang, Y., Yang, B., Wu, H., Peng, C., et al. (2020) · Oncogenesis · doi:10.1038/s41389-020-0226-z · Cited by 107
Close to the edge: Heterochromatin at the nucleolar and nuclear peripheries
Bizhanova, A., & Kaufman, P. D. (2020) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2020.194666 · Cited by 112
Disruption of the circadian clock drives Apc loss of heterozygosity to accelerate colorectal cancer
Chun, S. K., Fortin, B. M., Fellows, R. C., Habowski, A. N., Verlande, A., Song, W. A., Mahieu, A. L., Lefebvre, A. E. Y. T., Sterrenberg, J. N., Vélez, L. M., et al. (2022) · Science Advances · doi:10.1126/sciadv.abo2389 · Cited by 112
More than a metabolic enzyme: MTHFD2 as a novel target for anticancer therapy?
Zhu, Z., & Leung, G. K. K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00658 · Cited by 106
Fan, L., Peng, G., Sahgal, N., Fazli, L., Gleave, M. E., Zhang, Y., Hussain, A., & Qi, J. (2015) · Oncogene · doi:10.1038/onc.2015.309 · Cited by 106
Liu, C., Lou, W., Armstrong, C. M., Zhu, Y., Evans, C. P., & Gao, A. C. (2015) · The Prostate · doi:10.1002/pros.23015 · Cited by 106
Singleton, K. R., Crawford, L. A., Tsui, E. L., Manchester, H. E., Maertens, O., Liu, X., Liberti, M. V., Magpusao, A. N., Stein, E. M., Tingley, J. P., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.022 · Cited by 102
Wang, K., Elsayed, M., Wu, G., Deng, N., Cushman, M., & Yang, D. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b02679 · Cited by 106
Li, W., Gupta, S. K., Han, W., Kundson, R. A., Nelson, S., Knutson, D. L., Greipp, P. T., Elsawa, S. F., Sotomayor, E. M., & Gupta, M. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0761-2 · Cited by 109
MYC in cancer: from undruggable target to clinical trials
Whitfield, J. R., & Soucek, L. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01143-2 · Cited by 106
ZBTB7A acts as a tumor suppressor through the transcriptional repression of glycolysisPreprint
Liu, X., Haines, J. E., Mehanna, E. K., GENET, M. D., Ben‐Sahra, I., Asara, J. M., Manning, B. D., & Yuan, Z.-M. (2014) · Genes & Development · doi:10.1101/gad.245910.114 · Cited by 106
Yang, M., Liu, W., Pellicane, C., Sahyoun, C., Joseph, B. K., Gallo-Ebert, C., Donigan, M., Pandya, D., Giordano, C., Bata, A., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m041335 · Cited by 93
Stabilization of the c-Myc Protein by CAMKIIγ Promotes T Cell Lymphoma
Gu, Y., Zhang, J., Ma, X., Kim, B.-W., Wang, H., Li, J., Pan, Y., Xu, Y., Ding, L., Yang, L., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.001 · Cited by 105
Qin, X., Suzuki, H., Honda, M., Okada, H., Kaneko, S., Inoue, I., Ebisui, E., Hashimoto, K., Carninci, P., Kanki, K., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802279115 · Cited by 109
MYC as a Multifaceted Regulator of Tumor Microenvironment Leading to Metastasis
Meškytė, E. M., Keskas, S., & Ciribilli, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207710 · Cited by 109
The emerging structural complexity of G-quadruplex RNAs
Banco, M. T., & Ferré-D’Amaré, A. R. (2021) · RNA · doi:10.1261/rna.078238.120 · Cited by 102
Jung, L. A., Gebhardt, A., Koelmel, W., Ade, C. P., Walz, S., Kuper, J., von Eyss, B., Letschert, S., Redel, C., d'Artista, L., et al. (2017) · Oncogene · doi:10.1038/onc.2016.354 · Cited by 101
MYC: Master Regulator of Immune Privilege
Casey, S. C., Baylot, V., & Felsher, D. W. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.01.002 · Cited by 109
Lu, Y.-C., Sanada, C. D., Xavier-Ferrucio, J. M., Wang, L., Zhang, P., Grimes, H. L., Venkatasubramanian, M., Chetal, K., Aronow, B. J., Salomonis, N., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.084 · Cited by 106
Sirtuins' control of autophagy and mitophagy in cancer
Aventaggiato, M., Vernucci, E., Barreca, F., Russo, M. A., & Tafani, M. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107748 · Cited by 103
MYC Deregulation in Gastric Cancer and Its Clinicopathological Implications
de Souza, C. R. T., Leal, M. F., Calcagno, D. Q., Sozinho, E. K. C., Borges, B. D. N., Montenegro, R. C., dos Santos, Â. K. C. R., dos Santos, S. E. B., Ribeiro, H. F., de Assumpção, P. P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064420 · Cited by 103
Büchel, G., Carstensen, A., Mak, K. Y., Röschert, I., Leen, E. N., Sumara, O., Hofstetter, J., Herold, S., Kalb, J., Baluapuri, A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.090 · Cited by 106
C-myc Contributes to Malignancy of Lung Cancer: A Potential Anticancer Drug Target
Pithi Chanvorachote, B., Sriratanasak, N., & Nonpanya, N. (2020) · Anticancer Research · doi:10.21873/anticanres.13990 · Cited by 104
Zhou, S., Zhang, S., Wang, L., Huang, S., Yuan, Y., Yang, J., Wang, H., Li, X., Wang, P., Zhou, L., et al. (2020) · Oncogenesis · doi:10.1038/s41389-020-0218-z · Cited by 105
Yonesaka, K., Tanizaki, J., Maenishi, O., Haratani, K., Kawakami, H., Tanaka, K., Hayashi, H., Sakai, K., Chiba, Y., Tsuya, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3359 · Cited by 104
MYC function and regulation in physiological perspective
Jha, R., Kouzine, F., & Levens, D. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1268275 · Cited by 107
Methyl Jasmonate: Putative Mechanisms of Action on Cancer Cells Cycle, Metabolism, and Apoptosis
Cesari, I. M., Carvalho, É., Rodrigues, M. F., Mendonça, B. D. S., Amoêdo, N. D., & Rumjanek, F. D. (2014) · International Journal of Cell Biology · doi:10.1155/2014/572097 · Cited by 102
Andersen, A. P., Moreira, J. M. A., & Pedersen, S. F. (2014) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2013.0098 · Cited by 105
Metabolic flexibility in melanoma: A potential therapeutic target
Ruocco, M. R., Avagliano, A., Granato, G., Vigliar, E., Masone, S., Montagnani, S., & Arcucci, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.016 · Cited by 106
MYC and therapy resistance in cancer: risks and opportunities
Donati, G., & Amati, B. B. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13319 · Cited by 104
Korkut, A., Wang, W., Demir, E., Aksoy, B. A., Jing, X., Molinelli, E. J., Babur, Ö., Bemis, D. L., Sümer, S. O., Solit, D. B., et al. (2015) · eLife · doi:10.7554/elife.04640 · Cited by 99
Lin, X., Sun, R., Zhao, X., Zhu, D., Zhao, X., Gu, Q., Dong, X., Zhang, D., Zhang, Y., Li, Y., et al. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1452-x · Cited by 100
Iwai, K., Yaguchi, M., Nishimura, K., Yamamoto, Y., Tamura, T., Nakata, D., Dairiki, R., Kawakita, Y., Mizojiri, R., Ito, Y., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708289 · Cited by 101
JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma
Wong, M., Sun, Y., Xi, Z., Milazzo, G., Poulos, R. C., Bartenhagen, C., Bell, J. L., Mayoh, C., Ho, N., Tee, A. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11132-w · Cited by 99
Metabolic host response and therapeutic approaches to influenza infection
Keshavarz, M., Solaymani‐Mohammadi, F., Namdari, H., Arjeini, Y., Mousavi, M. J., & Rezaei, F. (2020) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-020-00211-2 · Cited by 102
The long journey to bring a Myc inhibitor to the clinic
Whitfield, J. R., & Soucek, L. (2021) · The Journal of Cell Biology · doi:10.1083/jcb.202103090 · Cited by 101
MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma
Maddipati, R., Norgard, R. J., Baslan, T., Rathi, K. S., Zhang, A. X. W., Saeid, A., Higashihara, T., Wu, F., Kumar, A., Annamalai, V., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1826 · Cited by 98
Stress-induced cleavage of Myc promotes cancer cell survivalPreprint
Conacci‐Sorrell, M., Ngouenet, C., Anderson, S., Brabletz, T., & Eisenman, R. N. (2014) · Genes & Development · doi:10.1101/gad.231894.113 · Cited by 107
The mTORC2‐Akt1 Cascade Is Crucial for c‐Myc to Promote Hepatocarcinogenesis in Mice and Humans
Xu, Z., Xu, M. M., Pin, L., Zhang, S., Shang, R., Qiao, Y., Che, L., Ribback, S., Cigliano, A., Evert, K., et al. (2019) · Hepatology · doi:10.1002/hep.30697 · Cited by 100
Röschert, I., Poon, E., Henssen, A. G., García, H. D., Gatti, M., Giansanti, C., Jamin, Y., Ade, C. P., Gallant, P., Schülein‐Völk, C., et al. (2021) · Nature Cancer · doi:10.1038/s43018-020-00171-8 · Cited by 103
Targeting of the MYCN Protein with Small Molecule c-MYC Inhibitors
Müller, I., Larsson, K., Frenzel, A., Oliynyk, G., Zirath, H., Prochownik, E. V., Westwood, N. J., & Arsenian‐Henriksson, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097285 · Cited by 97
Pi, M., Kuang, H., Yue, C., Yang, Q., Wu, A., Li, Y., Assaraf, Y. G., Yang, D., & Wu, S. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100822 · Cited by 98
Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma
Höllein, A., Fallahi, M., Schoeffmann, S., Steidle, S., Schaub, F. X., Rudelius, M., Laitinen, I., Nilsson, L. M., Goga, A., Peschel, C., et al. (2014) · Blood · doi:10.1182/blood-2014-06-584524 · Cited by 102
JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer*
Qiu, H., Jackson, A. L., Kilgore, J. E., Zhong, Y., Chan, L. L.-Y., Gehrig, P. A., Zhou, C., & Bae-Jump, V. L. (2015) · Oncotarget · doi:10.18632/oncotarget.3126 · Cited by 103
RetractedKowalik, M. A., Guzzo, G., Morandi, A., Perra, A., Menegon, S., Masgras, I., Trevisan, E., Angioni, M. M., Fornari, F., Quagliata, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8632 · Cited by 97
MYC protein expression is an important prognostic factor in acute myeloid leukemia
Ohanian, M. N., Rozovski, U., Kanagal‐Shamanna, R., Abruzzo, L. V., Loghavi, S., Kadia, T. M., Futreal, P. A., Bhalla, K. N., Zuo, Z., Huh, Y. O., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1464158 · Cited by 95
Metadata
- Authors
- Dang, C. V.
- Affiliations
- Abramson Cancer Center (US)
- Corresponding author
- Dang, Chi V.
- ORCID
- Dang, Chi V.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 149
- Issue
- 1
- Pages
- 22-35
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC3345192
- OpenAlex
- W2021536610
- Cited by
- 3,390
- References
- 232
- Citations by year
- 2026: 218 · 2025: 267 · 2024: 300 · 2023: 299 · 2022: 280 · 2021: 332 · 2020: 283 · 2019: 250 · 2018: 209 · 2017: 215 · 2016: 215 · 2015: 166 · 2014: 179 · 2013: 144 · 2012: 33
- FWCI
- 17.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA057341, R01CA051497, P30CA016520)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- MYC oncogene, tumor initiation, bromodomain proteins, MYC inhibitors, tumor growth inhibition, bioenergetics, glucose metabolism, glutamine metabolism, biomass accumulation, microRNA expression, cancer therapy
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Neoplasms, Gene Expression Regulation, Neoplastic, Genes, myc, Proto-Oncogene Proteins c-myc, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
